Annexon

US · ANNX #3455 by market cap Listed 2020

4.01 -0.02 -0.50%

Live - 5344 symbols - heartbeat 126s ago · 2026-10-08 09:08

Pre-market 4.03 +0.50%

After-hours 4.05 +1.00%

Overnight 4.05 +1.00%

Market cap: 760.21M
P/E (TTM): -3.55
P/B: 4.09
EPS: -1.34
Div yield: 0.00%
52W pos: 32%

Reader sentiment Are you bullish or bearish on ANNX?

Anonymous reader poll. Unscientific, not investment advice.

About Annexon

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Founded: 2011
CEO: Mr. Douglas Love, Esq.
Employees: 96
Headquarters: Brisbane, California, United States of America
Fiscal year end: 12-31
Website: annexonbio.com

Company profile

Exchange: US
Symbol: ANNX
Market-cap rank: #3455
Listing date: 2020-07-24
Market cap: 760.21M
Float cap: 656.68M
Shares out: 189.58M
Float shares: 163.76M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 09:08:31 · For reference only, not investment advice and not tailored to your situation.